GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia

Publisher： Bentham Science Publishers

E-ISSN： 1875-6190|3|1|45-62

ISSN： 1570-159X

Source： Current Neuropharmacology, Vol.3, Iss.1, 2005-01, pp. : 45-62

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adrenergic targets for the treatment of cognitive deficits in schizophrenia

By Arnsten Amy  

Psychopharmacology, Vol. 174, Iss. 1, 2004-06 ,pp. : 25-31

Springer Publishing Company

Access to resources Recommend Favorite

New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function

By  

Current Neuropharmacology, Vol. 13, Iss. 6, 2015-12 ,pp. : 793-801

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction

By  

Current Pharmaceutical Design, Vol. 21, Iss. 26, 2015-01 ,pp. : 3813-3828

Bentham Science Publishers

Access to resources Recommend Favorite

Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction

By Lewis David   Volk David   Hashimoto Takanori  

Psychopharmacology, Vol. 174, Iss. 1, 2004-06 ,pp. : 143-150

Springer Publishing Company

Access to resources Recommend Favorite

Omega 3 Fatty Acids: Novel Neurotherapeutic Targets for Cognitive Dysfunction in Mood Disorders and Schizophrenia?

By  

Current Neuropharmacology, Vol. 13, Iss. 5, 2015-09 ,pp. : 663-680

Bentham Science Publishers

Access to resources Recommend Favorite